Literature DB >> 29775292

Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6.

Nicholas J Porter1, Florence F Wagner2, David W Christianson1.   

Abstract

Among the metal-dependent histone deacetylases, the class IIb isozyme HDAC6 is remarkable because of its role in the regulation of microtubule dynamics in the cytosol. Selective inhibition of HDAC6 results in microtubule hyperacetylation, leading to cell cycle arrest and apoptosis, which is a validated strategy for cancer chemotherapy and the treatment of other disorders. HDAC6 inhibitors generally consist of a Zn2+-binding group such as a hydroxamate, a linker, and a capping group; the capping group is a critical determinant of isozyme selectivity. Surprisingly, however, even "capless" inhibitors exhibit appreciable HDAC6 selectivity. To probe the chemical basis for this selectivity, we now report high-resolution crystal structures of HDAC6 complexed with capless cycloalkyl hydroxamate inhibitors 1-4. Each inhibitor hydroxamate group coordinates to the catalytic Zn2+ ion with canonical bidentate geometry. Additionally, the olefin moieties of compounds 2 and 4 bind in an aromatic crevice between the side chains of F583 and F643. Reasoning that similar binding could be achieved in the representative class I isozyme HDAC8, we employed isothermal titration calorimetry to study the thermodynamics of inhibitor binding. These measurements indicate that the entropy of inhibitor binding is generally positive for binding to HDAC6 and negative for binding to HDAC8, resulting in ≤313-fold selectivity for binding to HDAC6 relative to HDAC8. Thus, favorable binding entropy contributes to HDAC6 selectivity. Notably, cyclohexenyl hydroxamate 2 represents a promising lead for derivatization with capping groups that may further enhance its impressive 313-fold thermodynamic selectivity for HDAC6 inhibition.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29775292      PMCID: PMC6030506          DOI: 10.1021/acs.biochem.8b00367

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  63 in total

Review 1.  Arginase: a binuclear manganese metalloenzyme.

Authors:  D E Ash; J D Cox; D W Christianson
Journal:  Met Ions Biol Syst       Date:  2000

2.  Development of a histone deacetylase 6 inhibitor and its biological effects.

Authors:  Ju-Hee Lee; Adaickapillai Mahendran; Yuanshan Yao; Lang Ngo; Gisela Venta-Perez; Megan L Choy; Nathaniel Kim; Won-Seok Ham; Ronald Breslow; Paul A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-10       Impact factor: 11.205

Review 3.  Structural basis for sirtuin activity and inhibition.

Authors:  Hua Yuan; Ronen Marmorstein
Journal:  J Biol Chem       Date:  2012-10-18       Impact factor: 5.157

Review 4.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Authors:  Katrina J Falkenberg; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2014-08-18       Impact factor: 84.694

5.  A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

Authors:  V M Richon; S Emiliani; E Verdin; Y Webb; R Breslow; R A Rifkind; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

6.  Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux.

Authors:  Qijun Wang; Yakun Zhang; Chen Yang; Hui Xiong; Yan Lin; Jun Yao; Hong Li; Lu Xie; Wei Zhao; Yufeng Yao; Zhi-Bin Ning; Rong Zeng; Yue Xiong; Kun-Liang Guan; Shimin Zhao; Guo-Ping Zhao
Journal:  Science       Date:  2010-02-19       Impact factor: 47.728

7.  iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM.

Authors:  T Geoff G Battye; Luke Kontogiannis; Owen Johnson; Harold R Powell; Andrew G W Leslie
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

8.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

Review 9.  HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination.

Authors:  C Boyault; K Sadoul; M Pabion; S Khochbin
Journal:  Oncogene       Date:  2007-08-13       Impact factor: 9.867

10.  Histone deacetylase 6 structure and molecular basis of catalysis and inhibition.

Authors:  Yang Hai; David W Christianson
Journal:  Nat Chem Biol       Date:  2016-07-25       Impact factor: 15.040

View more
  16 in total

1.  Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome.

Authors:  Alan P Kozikowski; Sida Shen; Marta Pardo; Maurício T Tavares; Dora Szarics; Veronick Benoy; Chad A Zimprich; Zsófia Kutil; Guiping Zhang; Cyril Bařinka; Matthew B Robers; Ludo Van Den Bosch; James H Eubanks; Richard S Jope
Journal:  ACS Chem Neurosci       Date:  2018-12-14       Impact factor: 4.418

Review 2.  Structure, mechanism, and inhibition of the zinc-dependent histone deacetylases.

Authors:  Nicholas J Porter; David W Christianson
Journal:  Curr Opin Struct Biol       Date:  2019-02-08       Impact factor: 6.809

3.  Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity.

Authors:  Nicholas J Porter; Jeremy D Osko; Daniela Diedrich; Thomas Kurz; Jacob M Hooker; Finn K Hansen; David W Christianson
Journal:  J Med Chem       Date:  2018-08-17       Impact factor: 7.446

4.  Structural Basis for the Selective Inhibition of HDAC10, the Cytosolic Polyamine Deacetylase.

Authors:  Corey J Herbst-Gervasoni; Raphael R Steimbach; Michael Morgen; Aubry K Miller; David W Christianson
Journal:  ACS Chem Biol       Date:  2020-07-23       Impact factor: 5.100

5.  Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.

Authors:  Nina Reßing; Melf Sönnichsen; Jeremy D Osko; Andrea Schöler; Julian Schliehe-Diecks; Alexander Skerhut; Arndt Borkhardt; Julia Hauer; Matthias U Kassack; David W Christianson; Sanil Bhatia; Finn K Hansen
Journal:  J Med Chem       Date:  2020-09-01       Impact factor: 7.446

6.  Binding of inhibitors to active-site mutants of CD1, the enigmatic catalytic domain of histone deacetylase 6.

Authors:  Jeremy D Osko; David W Christianson
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2020-08-19       Impact factor: 1.056

7.  Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.

Authors:  Andrew E Shouksmith; Justyna M Gawel; Nabanita Nawar; Diana Sina; Yasir S Raouf; Shazreh Bukhari; Liying He; Alexandra E Johns; Pimyupa Manaswiyoungkul; Olasunkanmi O Olaoye; Aaron D Cabral; Abootaleb Sedighi; Elvin D de Araujo; Patrick T Gunning
Journal:  ACS Med Chem Lett       Date:  2019-12-13       Impact factor: 4.345

8.  Methods for the expression, purification, and crystallization of histone deacetylase 6-inhibitor complexes.

Authors:  Jeremy D Osko; David W Christianson
Journal:  Methods Enzymol       Date:  2019-07-18       Impact factor: 1.600

Review 9.  Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6.

Authors:  Jeremy D Osko; David W Christianson
Journal:  Bioorg Med Chem Lett       Date:  2020-02-11       Impact factor: 2.823

10.  Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6.

Authors:  Jeremy D Osko; Nicholas J Porter; Poli Adi Narayana Reddy; You-Cai Xiao; Johanna Rokka; Manfred Jung; Jacob M Hooker; Joseph M Salvino; David W Christianson
Journal:  J Med Chem       Date:  2019-12-19       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.